WASHINGTON, D.C. (May 15, 2023) – The Association for Accessible Medicines Interim CEO, David Gaugh, today released the following statement regarding the U.S. Supreme Court's decision to decline hearing the GSK v. Teva case:
WASHINGTON DC (December 13, 2018) – “AAM applauds FDA Commissioner Scott Gottlieb and the agency for prioritizing consumer access to safe, high-quality, affordable generic medicines by withdrawing its proposed labeling rule. The agency correctly recognized the need for consistency and the potential for adverse consequences. The FDA’s action further exemplifies its focus on the best interest of the public’s health and provides patients with the utmost confidence in their health care choices.”